Edgar Filing: ABIOMED INC - Form 4

ABIOMED INC Form 4 May 18, 2007 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).								N OMB Number Expires: Estimate burden h response	Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response0.5		
(Print or Type	Responses)										
TERMEER HENRI A Syr				2. Issuer Name and Ticker or Trading Symbol ABIOMED INC [ABMD]				5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (Middle)	3. Date of Earliest Transaction (Chec				eck all applica	k all applicable)			
				(Month/Day/Year) 05/15/2007				_X_ Director 10% Owner Officer (give title Other (specify below) below)			
(Street) 4. If			4. If Am	. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check			
Filed(DANVERS, MA 01923			Filed(Mo	ed(Month/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tab	ole I - Non	-Derivativ	e Secu	rities Ac	quired, Disposed	of, or Benefi	cially Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/D	Date, if	Code (Instr. 8)	4. Securi ion(A) or D (Instr. 3,	ispose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, \$.01 par value	05/15/2007			А	1,254	A	\$ 11.96	55,805	D		
Common Stock, \$.01 par value								2,307,692	I	By Genzyme Corporation (3)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of
information contained in this form are not
required to respond unless the formSEC 1474
(9-02)

Edgar Filing: ABIOMED INC - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivatives Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Title and Amount of 8 Underlying Securities 1 (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) (<u>1)</u>	\$ 19.69					08/09/2001 <u>(2)</u>	08/09/2010	Common Stock	5,000
Stock Option (right to buy) (1)	\$ 18.4					08/08/2002 <u>(2)</u>	08/08/2011	Common Stock	5,000
Stock Option (right to buy) <u>(1)</u>	\$ 4.71					08/06/2003 <u>(2)</u>	05/21/2013	Common Stock	5,000
Common Stock (right to buy) <u>(1)</u>	\$ 5.15					08/13/2004 <u>(2)</u>	08/13/2013	Common Stock	5,000
Stock Option (right to buy) (4)	\$ 10.41					08/11/2005 <u>(2)</u>	08/11/2014	Common Stock	8,000
Stock Option (right to buy) (4)	\$ 10.06					08/09/2006 <u>(2)</u>	08/10/2015	Common Stock	8,000
Stock Option (right to buy) (4)	\$ 13.21					08/08/2007 <u>(2)</u>	08/09/2016	Common Stock	8,000

8. D So (I

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
TERMEER HENRI A C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS, MA 01923	Х						
Signatures							
/s/ Carrie-Ann Powierza (by po attorney)	ower of		05/18/2007				
<u>**</u> Signature of Reporting Perso	on	Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under ABIOMED, Inc. 1989 Non-Qualified Stock Option Plan for Non-Employee Directors.
- (2) This option becomes exercisable in full on the date set forth in Table II, Column 6.
- The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the (3) reporting person is the beneficial owner of such securities for the purposes of Section 16 or for any other purposes. The reporting person is the Chief Executive Officer of Genzyme Corporation.
- (4) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under ABIOMED, Inc. 2000 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.